A Candidate Vaccine Against Pulmonary Tuberculosis

The final analysis of a study on the M72/AS01_E candidate tuberculosis vaccine showed 49.7% protective efficacy at 3 years of follow-up.

The M72/AS01_E candidate vaccine against Mycobacterium tuberculosis is composed of a recombinant fusion protein, M72, derived from two M. tuberculosis antigens along with the AS01_E adjuvant. Previously, a placebo-controlled phase IIb trial was undertaken in three African countries on the efficacy of two intramuscular doses of the vaccine in preventing pulmonary tuberculosis in HIV-negative adults (aged 18–50) with latent tuberculosis based on a positive interferon-gamma release assay. A 2-year interim analysis showed 54% protective efficacy (NEJM JW Infect Dis Nov 2018 and N Engl J Med 2018; 379:162). The investigators now report on the efficacy, safety, and immunogenicity of the vaccine after 3 years of follow-up in the manufacturer-sponsor…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

A Candidate Vaccine Against Pulmonary Tuberculosis

Topics

Reviewing Author